Overview
- Washington set tariffs up to 100% on patented medicines from countries without preferred trade status, citing FDA data that most finished drugs and active ingredients now come from abroad.
- European Union, Japan, South Korea and Liechtenstein face a 15% rate, and the United Kingdom will have a tailored rate under its own trade agreement.
- Large manufacturers face a 120-day start to comply and smaller firms get 180 days, with a 90-day checkpoint to show progress in talks with companies and allied governments.
- Drugmakers that commit to move production to U.S. plants can qualify for reduced rates, and certain specialized or emergency-use therapies may receive exemptions.
- The package also keeps 50% tariffs on steel, aluminum and copper, with a 25% rate for items that contain those metals.